Protection against filovirus infection: virus-like particle vaccines

References

• Borio L, Inglesby T, Peters CJ et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA287(18), 2391–2405 (2002).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat. Med.10(12 Suppl.), S110–S121 (2004).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol.3(8), 677–685 (2003).
   PubMed Web of Science ®Google Scholar
• Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis.4(8), 487–498 (2004).
   PubMed Web of Science ®Google Scholar
• Leroy EM, Kumulungui B, Pourrut X et al. Fruit bats as reservoirs of Ebola virus. Nature438(7068), 575–576 (2005).
   PubMed Web of Science ®Google Scholar
• Towner JS, Pourrut X, Albarino CG et al. Marburg virus infection detected in a common African bat. PLoS ONE2(1), e764 (2007).
   PubMed Web of Science ®Google Scholar
• Bray M. Defense against filoviruses used as biological weapons. Antiviral Res.57(1–2), 53–60 (2003).
   PubMed Web of Science ®Google Scholar
• Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. Trends Microbiol.5(9), 408–416 (2007).
   Google Scholar
• Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d’Ivoire: clinical and biologic presentation. J. Infect. Dis.179(Suppl. 1), S48–S53 (1999).
   PubMed Web of Science ®Google Scholar
• Rollin PE, Williams RJ, Bressler DS et al. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from The Philippines to the United States. J. Infect. Dis.179(Suppl. 1), S108–S114 (1999).
   PubMed Web of Science ®Google Scholar
• Bausch DG, Borchert M, Grein T et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerging Infect. Dis.9(12), 1531–1537 (2003).
   PubMedGoogle Scholar
• WHO. Marburg Haemorrhagic Fever in Angola – Update 25. Epidemic and Pandemic Alert and Response (EPR), Disease Outbreak News, 24 August, 2005.
   Google Scholar
• WHO. Marburg Haemorrhagic Fever in Uganda. Epidemic and Pandemic Alert and Response (EPR), Disease Outbreak News, 3 August 2007.
   Google Scholar
• Towner JS, Khristova ML, Sealy TK et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol.80(13), 6497–6516 (2006).
   PubMed Web of Science ®Google Scholar
• Leroy EM, Rouquet P, Formenty P et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science303(5656), 387–390 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. Ebola Haemorrhagic Fever in the Democratic Republic of the Congo – Update 4. Epidemic and Pandemic Alert and Response (EPR), Disease Outbreak News, 20 February 2008.
   Google Scholar
• Aman MJ, Bosio CM, Panchal RG, Burnett JC, Schmaljohn A, Bavari S. Molecular mechanisms of filovirus cellular trafficking. Microbes Infect.5(7), 639–649 (2003).
   PubMed Web of Science ®Google Scholar
• Hartlieb B, Weissenhorn W. Filovirus assembly and budding. Virology344(1), 64–70 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott LH, Sanchez A, Holloway BP, Kiley MP, McCormick JB. Ebola protein analyses for the determination of genetic organization. Arch. Virol.133(3–4), 423–436 (1993).
   PubMed Web of Science ®Google Scholar
• Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res.29(3), 215–240 (1993).
   PubMed Web of Science ®Google Scholar
• Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl Acad. Sci. USA93(8), 3602–3607 (1996).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Volchkov VE, Volchkova VA, Klenk HD. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol.15(Suppl.), 159–169 (1999).
   Google Scholar
• Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol.72(8), 6442–6447 (1998).
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. USA95(10), 5762–5767 (1998).
   PubMed Web of Science ®Google Scholar
• Wool-Lewis RJ, Bates P. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J. Virol.73(2), 1419–1426 (1999).
   PubMed Web of Science ®Google Scholar
• Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science308(5728), 1643–1645 (2005).
   PubMed Web of Science ®Google Scholar
• Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol.80(8), 4174–4178 (2006).
   PubMed Web of Science ®Google Scholar
• Schnittler HJ, Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin. Infect. Dis.27(2), 404–406 (1998).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Larsen T et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol.163(6), 2347–2370 (2003).
   PubMed Web of Science ®Google Scholar
• Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med.5(8), 761–772 (2005).
   PubMedGoogle Scholar
• Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol.74(10), 4933–4937 (2000).
   PubMed Web of Science ®Google Scholar
• Simmons G, Rennekamp AJ, Chai N, Vandenberghe LH, Riley JL, Bates P. Folate receptor a and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J. Virol.77(24), 13433–13438 (2003).
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol.78(10), 5458–5465 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Guth AC et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire Ebolavirus bind a common receptor. J. Biol. Chem.281(23), 15951–15958 (2006).
   PubMed Web of Science ®Google Scholar
• Bwaka MA, Bonnet MJ, Calain P et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis.179(Suppl. 1), S1–S7 (1999).
   Web of Science ®Google Scholar
• Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J. Infect. Dis.179(Suppl. 1), ix–xvi (1999).
   PubMed Web of Science ®Google Scholar
• Rodriguez LL, De Roo A, Guimard Y et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis.179(Suppl. 1), S170–S176 (1999).
   PubMed Web of Science ®Google Scholar
• Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis.4(8), 487–498 (2004).
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis.178(3), 651–661 (1998).
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis.179(Suppl. 1), S203–S217 (1999).
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology239(1), 206–216 (1997).
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol.7(7), 556–567 (2007).
   PubMed Web of Science ®Google Scholar
• Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat. Immunol.8(11), 1159–1164 (2007).
   Google Scholar
• Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol. Med.12(5), 206–215 (2006).
   PubMed Web of Science ®Google Scholar
• Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine25(11), 1923–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infect. Dis.8(5), 503–507 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science287(5458), 1664–1666 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol.75(10), 4649–4654 (2001).
   PubMed Web of Science ®Google Scholar
• Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine25(6), 993–999 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol.75(6), 2660–2664 (2001).
   PubMed Web of Science ®Google Scholar
• Olinger GG, Bailey MA, Dye JM et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol.79(22), 14189–14196 (2005).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger G, Deal EM et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol.175(2), 1184–1191 (2005).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Perkins JG, Swenson DL et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J. Exp. Med.200(2), 169–179 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta M, Greer P, Mahanty S et al. CD8-mediated protection against Ebola virus infection is perforin dependent. J. Immunol.174(7), 4198–4202 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol.10(2), 229–235 (2000).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol.25(12), 3445–3451 (1995).
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int. Immunol.13(5), 633–641 (2001).
   Google Scholar
• Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8- dendritic cells: a dispensable role for TAP. Eur. J. Immunol.32(3), 818–825 (2002).
   PubMed Web of Science ®Google Scholar
• Guo L, Lu X, Kang SM, Chen C, Compans RW, Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology313(2), 502–513 (2003).
   PubMed Web of Science ®Google Scholar
• Crum CP, Rivera MN. Vaccines for cervical cancer. Cancer J.9(5), 368–376 (2003).
   Google Scholar
• Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol.76(10), 4855–4865 (2002).
   PubMed Web of Science ®Google Scholar
• Bavari S, Bosio CM, Wiegand E et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med.195(5), 593–602 (2002).
   PubMed Web of Science ®Google Scholar
• Licata JM, Johnson RF, Han Z, Harty RN. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol.78(14), 7344–7351 (2004).
   PubMed Web of Science ®Google Scholar
• Mittler E, Kolesnikova L, Strecker T, Garten W, Becker S. Role of the transmembrane domain of Marburg virus surface protein GP in assembly of the viral envelope. J. Virol.81(8), 3942–3948 (2007).
   Google Scholar
• Kallstrom G, Warfield KL, Swenson DL et al. Analysis of Ebola virus and VLP release using an immunocapture assay. J. Virol. Methods127(1), 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J. Virol.75(11), 5205–5214 (2001).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Kuehl K et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol. Med. Microbiol.40(1), 27–31 (2004).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bosio CM, Welcher BC et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl Acad. Sci. USA100(26), 15889–15894 (2003).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Moore BD, Warfield KL et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology326(2), 280–287 (2004).
   PubMed Web of Science ®Google Scholar
• Wahl-Jensen V, Kurz SK, Hazelton PR et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol.79(4), 2413–2419 (2005).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine22(25–26), 3495–3502 (2004).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine23(23), 3033–3042 (2005).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis.196(Suppl. 2), S430–S437 (2007).
   PubMed Web of Science ®Google Scholar
• Vzorov AN, Compans RW. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. J. Virol.74(18), 8219–8225 (2000).
   Google Scholar
• Ye L, Lin J, Sun Y et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology351(2), 260–270 (2006).
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Safrit JT, Lydy SL et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol.75(13), 5879–5890 (2001).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis.196(Suppl. 2), S421–S429 (2007).
   PubMed Web of Science ®Google Scholar
• Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for ebola virus in guinea pigs. Virus Res.92(2), 187–193 (2003).
   PubMed Web of Science ®Google Scholar
• Fuller CL, Ruthel G, Warfield KL et al. NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell. Microbiol.9(4), 962–976 (2007).
   PubMed Web of Science ®Google Scholar
• Moretta L, Biassoni R, Bottino C et al. Human NK cells and their receptors. Microbes Infect.4(15), 1539–1544 (2002).
   PubMed Web of Science ®Google Scholar
• Hart MK. Vaccine research efforts for filoviruses. Int. J. Parasitol.33(5–6), 583–595 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates. Nature424(6949), 681–684 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.PLoS Med.3(6), e177 (2006).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther.16(2), 149–156 (2005).
   PubMed Web of Science ®Google Scholar
• Santra S, Seaman MS, Xu L et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol.79(10), 6516–6522 (2005).
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med.11(7), 786–790 (2005).
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Stroher U et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in nonhuman primates: an efficacy assessment. Lancet367(9520), 1399–1404 (2006).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog.3(1), e2 (2007).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Zaki SR et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol.80(5), 2267–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK et al. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol.81(12), 6379–6388 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang L, Bukreyev A, Thompson CI et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol.79(2), 1113–1124 (2005).
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology251(1), 28–37 (1998).
   PubMed Web of Science ®Google Scholar
• Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol.79(16), 10442–10450 (2005).
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Palacios G, Towner JS et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J.20(14), 2519–2530 (2006).
   PubMed Web of Science ®Google Scholar